Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection

Purpose of review Anti-HIV-1 broadly neutralizing antibodies (bNAbs) are promising agents in the fight against the AIDS epidemic. Multiple bNAbs have been already evaluated in clinical trials with encouraging results. This review discusses the use of bNAbs for the prevention and treatment of HIV-1 infection, focusing on manufactured products that have been evaluated in clinical settings. Recent findings More than 17 bNAbs have been evaluated for safety and pharmacokinetics in humans. The vast majority presented a well tolerated profile and were generally well tolerated. Serum half-life varied from 12 to 73.5 days and can be improved by the addition of mutations to the Fc regions. Results from the antibody-mediated prevention (AMP) study show that VRC01, a CD4-binding-site bNAb, was effective at preventing the acquisition of sensitive HIV-1 strains but did not prevent the acquisition of strains whose in vitro sensitivity to the antibody had an IC80 of more than 1 mu g/ml. New bNAb combinations to improve coverage are currently being evaluated. In this review, we discuss the current landscape of HIV-1 bNAbs in clinical development. We also present the current strategies employed to improve the breadth, potency, serum half-life, effector function and administration of these compounds.

Automated summary

This article reviews the use of anti-HIV-1 broadly neutralizing antibodies (bNAbs) for the prevention and treatment of HIV-1 infection. Multiple bNAbs have shown promising results in clinical trials. The article also discusses the current landscape of HIV-1 bNAbs in clinical development and the strategies employed to improve their breadth, potency, serum half-life, effector function, and administration.